Free Trial
NASDAQ:EXOZ

eXoZymes Q1 2026 Earnings Report

eXoZymes logo
$7.80 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$7.73 -0.07 (-0.90%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

eXoZymes EPS Results

Actual EPS
-$0.28
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

eXoZymes Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

eXoZymes Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
4:00PM ET

Earnings Documents

eXoZymes Earnings Headlines

Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
See More eXoZymes Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like eXoZymes? Sign up for Earnings360's daily newsletter to receive timely earnings updates on eXoZymes and other key companies, straight to your email.

About eXoZymes

eXoZymes (NASDAQ:EXOZ), Inc. develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide. Headquartered in the United States, the company distributes its products through direct sales and a global network of distributors, positioning itself to support growth in both research and diagnostic markets.

View eXoZymes Profile